# Social spatial navigation assessment for early-stage Alzheimer's disease

> **NIH NIH R21** · BRIGHAM AND WOMEN'S HOSPITAL · 2021 · $190,054

## Abstract

Project Summary
 Alzheimer’s disease (AD) is a public health epidemic, laying an enormous mental, physical, and financial
burden on individuals, families, and societies. Despite significant research efforts around the world, the specific
link between cognitive / functional deficits and the underlying pathology remains unclear. Critical to solving this
is the evaluation of novel cognitive tests within cohorts that have detailed biomarkers for AD pathophysiology.
Widely used cognitive tests for AD focus on episodic memory deficits, but recent work led by us and others
indicates that tests of spatial navigation and orientation may provide significantly more accurate detection of the
earliest signatures of AD. Our hypothesis is that integrating tests of navigation and orientation (to people, places,
and events) into one test will prove particularly sensitive. Currently no such test exists.
 Our aim is to develop and evaluate a novel ecologically valid cognitive test which probes both navigation and
orientation in order to assess cognitively normal older adults (CN), amnestic mild cognitive impairment (MCI),
and mild AD dementia participants from two ongoing imaging studies (R01 AG053184 and R01 AG067021) of
the Principal Investigator (PI), Dr. Gad Marshall. Participants will undergo amyloid and tau positron emission
tomography (PET) as part of those studies, which we will leverage in relating those biomarker findings to our
novel cognitive test across the early AD continuum. Creating the new test will require combining the expertise of
Co-PI Dr. Hugo Spiers (expert in spatial navigation) and Co-PI Dr. Shahar Arzy (expert in orientation). Dr. Spiers
has recently developed a virtual reality (VR)-based assessment tool for smartphone and tablet devices that has
tested 4.3 million participants on their navigation ability. While this enables an unparalleled opportunity for
machine learning to detect subtle impairments, the task is not tailored to the individual’s personal world, which
clinical experience as well as research from the Co-PI, Dr. Arzy, indicate to be critical in AD. We therefore
propose to develop a novel patient-tailored digital personalized tool for the diagnosis and monitoring of early-
stage AD. Building on our recent work, Google Street View (GSV) images will be used to display and enable
navigation of the participant’s familiar environment. Overlaid text messages will pop up to provide information
about the overriding cover-story and to test navigation and orientation. We will benchmark how hard each
person’s environment is to navigate using reinforcement learning (RL) agents trained on the local street
networks. Functional magnetic resonance imaging (fMRI) will be used to understand the brain networks engaged
by the new task and allow a comparison with the pathological and clinical data collected by Dr. Marshall. Machine
learning models will be used to detect subtle impairment in the individual participant level. Following Dr. Spiers’
...

## Key facts

- **NIH application ID:** 10126352
- **Project number:** 1R21AG070877-01
- **Recipient organization:** BRIGHAM AND WOMEN'S HOSPITAL
- **Principal Investigator:** Shahar Arzy
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $190,054
- **Award type:** 1
- **Project period:** 2021-03-01 → 2023-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10126352

## Citation

> US National Institutes of Health, RePORTER application 10126352, Social spatial navigation assessment for early-stage Alzheimer's disease (1R21AG070877-01). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10126352. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*